(Q40693601)

22 September 2017

title

Phase II study of vinorelbine in patients with androgen-independent prostate cancer (English)

1 reference

22 September 2017

S Oudard

1

1 reference

22 September 2017

A Caty

2

1 reference

22 September 2017

Y Humblet

3

1 reference

22 September 2017

M Beauduin

4

1 reference

22 September 2017

E Suc

5

1 reference

22 September 2017

M Piccart

6

1 reference

22 September 2017

F Rolland

7

1 reference

22 September 2017

P Fumoleau

8

1 reference

22 September 2017

R Bugat

9

1 reference

22 September 2017

P Houyau

10

1 reference

22 September 2017

A Monnier

11

1 reference

22 September 2017

X Sun

12

1 reference

22 September 2017

P Montcuquet

13

1 reference

22 September 2017

J Breza

14

1 reference

22 September 2017

J Novak

15

1 reference

22 September 2017

T Gil

16

1 reference

22 September 2017

D Chopin

17

1 reference

22 September 2017

publication date

1 June 2001

1 reference

22 September 2017

1 reference

22 September 2017

volume

12

1 reference

22 September 2017

issue

6

1 reference

22 September 2017

page(s)

847-852

1 reference

22 September 2017

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

A Review of the Antitumour Activity of Vinorelbine in Breast Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Inhibition of prostate cancer growth by vinblastine and tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011141611560

7 January 2021

Identifiers

DOI

10.1023/A:1011141611560

1 reference

22 September 2017

1 reference